An Open-Label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies

Trial Profile

An Open-Label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Alisertib (Primary)
  • Indications Anaplastic large cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; MALT lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 11 Sep 2017 Results (n=671) of population PK analysis using patient data from 6 Phase 1, 1 Phase 1/2 and 3 Phase 2 clinical trials published in the British Journal of Clinical Pharmacology
    • 29 Mar 2017 Time frame of primary endpoint has changed from 12 months to up to 422 days and treatment arms changed from 1 to 3.
    • 29 Mar 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top